Kala Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

15 Apr 2026

KALA

10-K: Kala Bio Shifts Focus to AI Platform Amidst Biologics Discontinuation

Kala Bio, Inc. announces a strategic pivot towards developing an AI infrastructure platform for the biotech industry, following the discontinuation of its KPI-012 biologics program.

NASDAQ

31 Mar 2025

KALA

Kala Bio, INC

10-K: KALA BIO, Inc. Reports FY2024 Results, Highlights KPI-012 Clinical Progress

KALA BIO, Inc. files its 10-K, summarizing its financial results for 2024 and providing updates on the clinical development of KPI-012 for persistent corneal epithelial defects (PCED).

NASDAQ

29 Mar 2024

KALA

Kala Bio, INC

10-K: Kala Bio, Inc. Details Capital Structure and Regulatory Landscape in 10-K Filing

Kala Bio, Inc.'s 10-K filing outlines its capital structure, ongoing clinical trials for KPI-012, and regulatory considerations.